23andMe Holding Co. (ME) EBITDA Margin: -82.07%
Is 23andMe Holding Co.’s EBITDA margin high or low?
23andMe Holding Co.'s EBITDA margin of -82.07% is in line with its 5-year average of -86.99%, near the high end of its 5-year range (-132.89%–-62.69%).
As of Wednesday, June 17, 2026. 23.64% above its 12-month average of -107.48%.
ME EBITDA Margin Chart
ME Average EBITDA Margin Chart
ME Current vs Average EBITDA Margin Chart
ME EBITDA Margin Metrics
EBITDA MARGIN
-82.07%
EBITDA MARGIN AVG TTM
-107.48%
EBITDA MARGIN AVG 3Y
-97.90%
EBITDA MARGIN AVG 5Y
-86.99%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+23.64%
CURRENT VS 3Y AVG
+16.17%
CURRENT VS 5Y AVG
+5.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | -82.07% | -107.48% | -97.90% | -86.99% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.01B | -1.25% | -7.46% | -6.38% | 1.15% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.11B | 7.60% | 6.80% | 0.29% | -7.92% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.70B | 48.39% | -17.53% | -54.94% | 28.49% |
| Tempus AI, Inc. (TEM)vs › | $8.51B | -17.48% | -52.76% | -51.11% | -63.28% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | 10.23% | 12.29% | 18.59% | 20.64% |
| Baxter International Inc. (BAX)vs › | $10.19B | 6.81% | 8.65% | 4.13% | 9.00% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -7.64% | -4.75% | -0.21% | 1.54% |
| Revvity, Inc. (RVTY)vs › | $10.91B | 23.20% | 26.85% | 28.84% | 31.56% |
| Align Technology, Inc. (ALGN)vs › | $12.43B | 18.98% | 19.70% | 20.24% | 21.46% |
Margin Comparison
Gross Margin
53.3%
EBITDA Margin
-82.1%
Operating Margin
-114.0%
Net Margin
-134.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
23andMe Holding Co. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. EBITDA Margin FAQ
- What is the EBITDA margin for 23andMe Holding Co. (ME)?
- The EBITDA margin for ME stock is -82.07%.
- Is 23andMe Holding Co.'s EBITDA margin high or low?
- 23andMe Holding Co.'s EBITDA margin of -82.07% is in line with its 5-year average of -86.99%, near the high end of its 5-year range (-132.89%–-62.69%).
- What is the TTM average EBITDA margin for 23andMe Holding Co. (ME)?
- The TTM average EBITDA margin for ME stock is -107.48%.
- What is the 3Y average EBITDA margin for 23andMe Holding Co. (ME)?
- The 3Y average EBITDA margin for ME stock is -97.90%.
- What is the 5Y average EBITDA margin for 23andMe Holding Co. (ME)?
- The 5Y average EBITDA margin for ME stock is -86.99%.
23andMe Holding Co. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-03-31 | -82.07% |
| 2024-03-31 | -132.89% |
| 2023-03-31 | -92.80% |
| 2022-03-31 | -83.86% |
| 2021-03-31 | -67.62% |
| 2020-03-31 | -62.69% |
| 2019-03-31 | -39.38% |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage